Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications

Annals of the New York Academy of Sciences

Volumn 878, Issue , 1999, Pages 212-227

  Zucker, Stanley ^a,b   Hymowitz, Michelle ^a   Conner, Cathleen ^a   Zarrabi, Hosein M ^a   Hurewitz, Adam N ^b   Matrisian, Lynn ^c   Boyd, Douglas ^d   Nicolson, Garth ^e   Montana, Steve ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

BLADDER CANCER; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; ENZYME ACTIVATION; ENZYME SYNTHESIS; HUMAN; METASTASIS; PROSTATE CANCER; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032836427     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07687.x     Document Type: Conference Paper

References (75)

1. 1. Stetler-Stevenson, W.G. 1995. Proteinase A activation during tumor cell invasion. Invasion Metastasis 14: 259-268.
2. 2. Birkedal-Hansen, H., W.G.I. Moore, M.K. Bodden et al. 1993. Matrix metalloproteinases: a review. Crit. Rev. Bio. Med. 42: 197-250.
3. 3. Poulsom, R., M. Pignatelli, W.G. Stetler-Stevenson et al. 1992. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am. J. Pathol. 141: 389-394.
4. 4. Emmert-Buck, M.R., M.J. Roth, Z. Zhuang et al. 1994. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am. J. Pathol. 145: 1285-1290.
5. 5. Pyke, C., E. Ralfkiaer, K. Tryggvason et al. 1993. Messenger RNA for two types of type IV collagenases is located in stromal cells in human colon cancer. Am. J. Pathol. 142: 359-365.
6. 6. Wood, M., K. Fudge, J.L. Mohler et al. 1997. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 in human prostate cancer. Clin. Exp. Metastasis 15: 246-258.
7. 7. Polette, M., C. Gilles, B. Nawrocki et al. 1997. TCSF expression and localization in human lung and breast cancer. J. Histochem. Cytochem. 45: 703-709.
8. 8. Hewitt, R. E., I.H. Leach, D.G. Powe et al. 1991. Distribution of collagenase and tissue inhibitors of metalloproteinases (TIMP) in colorectal tumours. Int. J. Cancer 49: 666-672.
9. 9. Okada, A., J.-B. Bellocq, N. Rouyer et al. 1995. Membrane-type matirx metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. USA 92: 2730-2734.
10. 10. Porte, H., E. Chastre, S. Prevot et al. 1995. Neoplastic progression of human colorectal cancer is associated with overexpression of stromelysin-3 and BM-40/ SPARC genes. Int. J. Cancer 64: 70-75.
11. 11. Urbanski, S.J., D.R. Edwards, N. Hershfield et al. 1993. Expression pattern of metalloproteinases and their inhibitors changes with progression of human sporatic colorectal neoplasia. Diagnostic Mol. Pathol. 2: 81-89.
12. 12. Heppner, K.J., L.M. Matrisian, R.A. Jensen et al. 1996. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Amer. J. Pathol. 149: 273-282.
13. 13. Zeng, Z.S., Y. Huang, A.M. Cohen et al. 1996. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J. Clin. Oncol. In press.
14. 14. Jeziorska, M., N.Y. Haboubi, P.F. Schofield et al. 1994. Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma. Int. J. Colorect. Dis. 9: 141-148.
15. 15. Newell, K.J., J.P. Witty, W.H. Rodgers et al. 1994. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Molec. Carcinogenesis 10: 199-206.
16. 16. Yoshimoto, M., F. Itoh, H. Yamamoto et al. 1993. Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. Int. J. Cancer 54: 614-618.
17. 17. Sato, H., T. Takino, Y. Okada et al. 1994. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65.
18. 18. Strongin, A.Y., I. Collier, G. Bannicov et al. 1995. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase. J. Biol. Chem. 270: 5331-5338.
19. 19. Zucker, S., C. Conner, B.I. DiMassimo et al. 1995. Thrombin induces the activation of progelatinase A in vascular endothelial cells: Physiologic regulation of angiogenesis. J. Biol. Chem. 270: 23730-23738.
20. 20. Nomura, H., H. Sato, M. Seiki et al. 1995. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 55: 3263-3266.
21. 21. Basset, P., J.P. Bellocq, C. Wolf et al. 1990. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348: 699-704.
22. 22. Zucker, S., R.M. Lysik, B.I. DiMassimo et al. 1995. Plasma assay of gelatinase B:tissue inhibitor of metalloproteinase (TIMP) complexes in cancer. Cancer 76: 700-708.
23. 23. Kataoka, H., R. DeCastro, S. Zucker et al. 1993. The tumor cell-derived collagenase stimulating factor, TCSP, increases expression of interstitial collagenase, stromelysin and 72 kDa gelatinase. Cancer Res. 53: 3155-3158.
24. 24. Guo, H., S. Zucker, M. Gordon et al. 1997. Stimulation of metalloproteinase production by recombinant EMMPRIN from transfected CHO cells. J. Biol. Chem. 272: 24-27.
25. 25. Allgayer, H., R. Babic, B.C. M. Beyer et al. 1998. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncology 55: 152-160.
26. 26. Murray, G.I., M.E. Duncan, P. O'Neil et al. 1996. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med. 2: 461-462.
27. 27. Zeng, Z. S. & J. G. Guillem. 1995. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br. J. Cancer 72: 575-582.
28. 28. Zeng, Z. S., Y. Huang, A.M. Cohen et al. 1996. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J. Clin. Oncol. 14: 3133-3140.
29. 29. Brown, P.D., R. E. Bloxidge, E. Anderson et al. 1993. Expression of activated gelatinase in human invasive breast cancer. Clin. Exp. Metastasis 11: 183-189.
30. 30. Davies, B., D.W. Miles, L.C. Haperfield et al. 1993. Activity of type IV collagenases in benign and malignant breast disease. Br. J. Cancer 67: 1126-1131.
31. 31. Liabakk, N.-B., E. Talbot, R.A. Smith et al. 1996. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 56: 190-196.
32. 32. Murnane, M.J., S. Shuja, E. Del Re et al. 1997. Characterizing human colorectal carcinomas by proteolytic profile in vivo 11: 209-216.
33. 33. Nielsen, B.S., S. Timshel, L. Kiedsen et al. 1996. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int. J. Cancer 65: 57-62.
34. 34. Malik, N., B.W. Greenfield, A.F. Wahl, et al. 1996. Activtion of human monocytes through CD40 induces matrix metalloproteinases. J. Immunol. 156: 3952-3960.
35. 35. Lu, X., M. Levy, I.B. Weinstein et al. 1991. Immunologic quantification of levels of tissue inhibitor of metalloproteinase-I in human colon cancer. Cancer Res. 51: 6231-6235.
36. 36. Stearns, M. & M.E. Stearns. 1996. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncology Res. 8: 69-75.
37. 37. Festuccia, C., M. Bologna, C. Vicentini et al. 1996. Increased matrix metalloproteinase-9 secretion in short-term cultures of prostatic tumor cells. Int. J. Cancer 69: 386-393.
38. 38. Kanayama, H.-O., K.-Y. Yokoto, Y. Kurokawa et al. 1998. Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82: 1359-1366.
39. 39. Zucker, S., R.M. Lysik, M. Gurfinkel et al. 1992. Immunoassay of type IV collagenase/gelatinase (MMP-2) in human plasma. J. Immunol. Meth. 148: 189-198.
40. 40. Cooksley, S., J.P. Hipkiss, S.P. Tickle et al. 1990. Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 10: 285-291.
41. 41. Fujimot, N., J. Zhang, K. Iwata et al. 1993. A one step sandwich immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies. Clin. Chim. Acta 220: 31-45.
42. 42. Clark, I.M., L. Powell, J.K. Wright et al. 1992. Monoclonal antibodies against human fibroblast collagenase and the design of an enzyme-linked immunosorbent assay to measure total collagenase. Matrix 12: 475-480.
43. 43. Ohuchi, E., I. Azumano, S. Yoshida et al. 1996. A one-step enzyme immunoassay for human matirx metalloproteinase 7 (matrilysin) using monoclonal antibodies. Clin. Chim. Acta 244: 181-198.
44. 44. Kjeldsen, L., O.W. Bjerrun, D. Hovgaard et al. 1992. Human neutrophil gelatinase: A marker for circulating neutrophils. Purification and quantification by enzyme linked immunosorbent assay. Eur. J. Haematol. 49: 180-191.
45. 45. Zucker, S., R.M. Lysik, M.H. Zarrabi et al. 1993. Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 53: 140-146.
46. 46. Moscatelli, D. & D.B. Rifkin, 1988. Membrane and matrix localization of proteinases: a common theme in tumor invasion and angiogenesis. Biochim. Biophys. Acta 948: 67-84.
47. 47. Zucker, S., R.M. Lysik, M.H. Zarrabi et al. 1992. Type IV collagenase/gelatinase (MMP2) is not increased in plasma of patients with cancer. Cancer Epidemiol. Biomark, and Prevent. 1: 475-479.
48. 48. Fujimoto, N., N. Mouri, K. Iwata et al. 1993. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin. Chim. Acta 221: 91-103.
49. 49. Garbisa, S., G. Scagljotti, L. Masiero et al. 1992. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 52: 4548-4549.
50. 50. Gohji, K., N. Fujimoto, A. Fujie et al. 1996. Prognostic significance of curculating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res. 56: 3196-3198.
51. 51. Gohji, K., N. Fujimoto, T. Komiyama et al. 1996. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78: 2379-2387.
52. 52. Naruo, S., H.-O. Kanayama, H. Takigawa et al. 1994. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. Int. J. Cancer 1: 228-231.
53. 53. Gohji, K., N. Fujimoto, I. Hara et al. 1998. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer 79: 96-101.
54. 54. Hayasaka, A., N. Suzuki, N. Fujimoto et al. 1996. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 24: 1058-1062.
55. 55. Baker, T., S. Tickle, H. Wasan et al. 1994. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br. J. Cancer 70: 506-512.
56. 56. Zucker, S., R.M. Lysik, M.H. Zarrabi et al. 1994. Elevated plasma stromelysin levels in arthritis. J. Rheumatol. 21: 2329-2333.
57. 57. Jung, K., L. Nowak, M. Lein et al. 1997. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int. J. Cancer 74: 220-223.
58. 58. Zucker, S., N. Mian, M. Drews et al. 1998. Increased serum stromelysin-1 in systemic lupus erythematosus: lack of correlation with disease activity. J. Rheumatol. 26: 78-80.
59. 59. Wilson, C.L. & L.M. Matrisian. 1996. Matrilysin: an epithelial matrix metallopro.teinase with potentially novel functions. Int. J. Biochem. Cell. Biol. 28: 123-136.
60. 60. Moses, M.A., D. Wiederschain, K.R. Loughlin et al. 1998. Incresed incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 58: 1395-1399.
61. 61. Taylor, D.T., N.T. Cheung & P.T. Dawes. 1994. Increased serum pro-MMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann. Rheum. Dis. 21: 768-772.
62. 62. Manicourt, D.-H., N. Fujimoto, K. Obata et al. 1995. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relation to serum levels of keratin sulfate and systemic parameters of inflammation. Arth. Rheum. 38: 1031-1039.
63. 63. Sasaki, S., H. Iwata, N. Ishiguro et al. 1994. Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin. Rheumatol. 13: 228-233.
64. 64. Bailey, C.J., R.M. Hembry, A. Alexander et al. 1994. Distribution of the matrix metalloproteinases stromelysin, gelatinase A and B, and collagenase in Chron's disease and normal intestines. J. Clin. Pathol. 47: 113-116.
65. 65. Lieber, C.S. 1994. Alcohol and the liver: 1994 update. Gastroenterology 106: 1085-1105.
66. 66. Arthur, M.J.P. 1995. Collagenase and liver fibrosis. J. Hepatology 22 (Suppl. 2): 43-48.
67. 67. George, D.K., G.A. Ramm, L.W. Powell et al. 1998. Evidence for altered hepatic matrix degradation in genetic haemochromatosis. Gut 42: 715-720.
68. 68. Arai, M., M. Nhoka, K. Maruyama et al. 1996. Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon. Digest. Dis. Sci. 41: 995-1000.
69. 69. Dollery, C.M., J.R. McEwan & A.M. Henney. 1995. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77: 863-868.
70. 70. Hirohata, S., S. Kusachi, M. Murakami et al. 1997. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infaction. Heart 78: 278-284.
71. 71. Tu, F.F., R.L. Goldenberg, M.B. Dubard, T. Tamura et al. 1998. Plasma matrix metalloproteinase-9 (MMP-9) levels as predictors of spontaneous preterm birth. Obstet. Gynecol. 92: 446-449.
72. 72. Kolben, M., A. Lopens, J. Blaser et al. 1996. Proteases and their inhibitors are indicative of gestational age. Eur. J. Obstet. Gynecol. 68: 59-65.
73. 73. Osmers, R.G.W., B.C. Adelmann-Grill, W. Rath et al. 1995. Biochemical events in cervical ripening dilatation during pregnancy and parturition. J. Obstet. Gynaecol. 21: 185-194.
74. 74. Rajabi, M., D.D. Dean & J.F. Woessner. 1987. High levels of serum collagenase in premature labor: A potential biochemical marker. Obstet. Gynecol. 69: 6166-6170.
75. 75. Clark, I.M., J.J. Morrison, G.A. Hackett et al. 1994. Tissue inhibitors of metalloproteinases: Serum levels during pregnancy and labor, term and preterm. Obstet. Gynecol, 83: 532-537.